title: High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome.
abstract: Recently, it was reported that remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome could be complicated with solid tumors. In a retrospective, multicenter study between October, 2003 and September, 2010, we investigated the characteristics of patients with paraneoplastic RS3PE syndrome  who fulfilled following criteria: (1) bilateral pitting edema of hands or feet or both, (2) sudden onset of polyarthritis, and (3) age >50 years, (4) seronegativity for rheumatoid factor (RF). A total of 33 cases fulfilled the above criteria. Eight patients (seven men and one woman) developed cancer within 2 years of RS3PE syndrome onset. There was no significant difference between the neoplastic and nonneoplastic groups in the proportions of patients with fever, symmetrical polyarthritis, pitting edema, and good response to corticosteroids. Serum matrix metalloproteinase 3 (MMP-3) level (median 437.3 ng/ml) in the paraneoplastic RS3PE patients was significantly higher than that in patients without neoplasia (median 114.7 ng/ml) (p < 0.05). We found that high serum MMP-3 is characteristic of patients with paraneoplastic RS3PE syndrome.
authors.affiliation: Department of Rehabilitation Sciences, Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki, 852-8520, Japan. origuchi@nagasaki-u.ac.jp
authors.forename: Tomoki
authors.initials: T
authors.lastname: Origuchi
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Arima
authors.forename: Shin-Ya
authors.initials: SY
authors.lastname: Kawashiri
authors.forename: Mami
authors.initials: M
authors.lastname: Tamai
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yamasaki
authors.forename: Hideki
authors.initials: H
authors.lastname: Nakamura
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Tsukada
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Aramaki
authors.forename: Masako
authors.initials: M
authors.lastname: Furuyama
authors.forename: Taiichiro
authors.initials: T
authors.lastname: Miyashita
authors.forename: Yojiro
authors.initials: Y
authors.lastname: Kawabe
authors.forename: Nozomi
authors.initials: N
authors.lastname: Iwanaga
authors.forename: Kaoru
authors.initials: K
authors.lastname: Terada
authors.forename: Yukitaka
authors.initials: Y
authors.lastname: Ueki
authors.forename: Takaaki
authors.initials: T
authors.lastname: Fukuda
authors.forename: Katsumi
authors.initials: K
authors.lastname: Eguchi
authors.forename: Atsushi
authors.initials: A
authors.lastname: Kawakami
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001168:Arthritis / Q000097:blood / Q000150:complications / Q000175:diagnosis; D015415:Biomarkers / Q000097:blood; D004487:Edema / Q000097:blood* / Q000150:complications / Q000175:diagnosis; D005121:Extremities; D005260:Female; D006801:Humans; D008297:Male; D019278:Matrix Metalloproteinase 3 / Q000097:blood*; D010257:Paraneoplastic Syndromes / Q000097:blood* / Q000150:complications / Q000175:diagnosis; D012189:Retrospective Studies; D012217:Rheumatoid Factor / Q000097:blood; D012698:Serologic Tests; D013585:Synovitis / Q000097:blood* / Q000150:complications / Q000175:diagnosis
chemical_list: D015415:Biomarkers; D012217:Rheumatoid Factor; C511768:MMP3 protein, human; D019278:Matrix Metalloproteinase 3